France Parkinson Association
11
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
9.1%
1 terminated/withdrawn out of 11 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED)
Role: collaborator
Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease
Role: collaborator
Efficacy of Ericksonian Hypnosis in the Management of Chronic Pain Related to Parkinson's Disease
Role: collaborator
Markers of Disease Progression and Gait Within the Parkinsonian Population
Role: collaborator
Training of Nursing Home Professionals and Quality of Life of Residents With Parkinson's Disease
Role: collaborator
The Effect of an Auditory Rhythmic Cue on the Frequency of Rolling in Patients with Dysphagia and Parkinson's Disease
Role: collaborator
Single-center Pathophysiological Study of the Role of Inflammation, Changes in the Intestinal Epithelial Barrier and the Intestinal Microbiota in Parkinson's Disease
Role: collaborator
Preliminary Study of the Quality of the Oral Flora in Parkinson's Patients
Role: collaborator
One-year Follow-up of Iron in Basal Ganglia - R2*: a Biomarker of Parkinson's Disease Progression?
Role: collaborator
Study of Dysarthria, Swallowing Disorders and Respiratory in Parkinson's Disease
Role: collaborator
Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET
Role: collaborator
All 11 trials loaded